Results 91 to 100 of about 19,727 (209)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation

Journal of Education, Health and Sport, 2018
Sofosbuvir is a drug, which has been found useful in HCV (Hepatis C Virus) therapy. It replaced the previously used interferon, the applied of which has shown many side effects or lack of response to treatment.
Katarzyna Lipa, Magdalena Julia Jabłońska, Patryk Kaczor, Kamil Leis, Krystian Kałużny, Przemysław Gałązka   +5 more
doaj   +1 more source

Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]

, 2018
BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia, DE SANTIS, Adriano, GINANNI CORRADINI, Stefano, Lattanzi, Barbara, Lupo1, Marinella, Maria Galluzzo, Clementina, Mennini, Gianluca, Merli, Manuela, Michelini, Zuleika, Palmisano, Lucia, Rossi, Massimo   +10 more
core   +1 more source

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022–June 2023

Journal of Viral Hepatitis, Volume 33, Issue 1, January 2026.
ABSTRACT Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontières implemented a simplified, decentralised model for HCV screening and treatment at a government‐run primary health centre (PHC) in Baldia Town, Karachi, Pakistan.
Sara Mazzilli, Muhammad K. Aslam, Mubashir Ahmed, Yves Wailly, Marta Miazek, Sana Ashraf, Ashok Ravji, William A. de Glanville, Petros Isaakidis   +8 more
wiley   +1 more source

Direct-acting antivirals and visceral leishmaniasis: A case report [PDF]

, 2019
Background: Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions ...
Cascio, A., Cervo, A., Colomba, C., Di Carlo, P., Firenze, A., Saporito, L., Tolomeo, M., Trizzino, M.   +7 more
core   +1 more source

The Global Burden of Hepatitis B From 1990 to 2021: Trends, Socioeconomic Inequalities, and Predictions to 2035

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Background Hepatitis B remains a global threat with significant disparities. This study provides a comprehensive assessment of its long‐term burden, inequalities, and future trajectories to inform elimination strategies. Methods Using data from the Global Burden of Disease Study 2021, we analyzed age‐standardized rates (ASRs) of incidence, prevalence ...
Miaoqing Ye, Xinzhu Guan, Panyue Yan, Yujie Guan, Minying Li, Yilin Yang, Jinyu He, Wenping Liu, Dong Deng, Zhiwen Luo   +9 more
wiley   +1 more source

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

The Saudi Journal of Gastroenterology, 2019
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline ...
Mohammed A Babatin, Abdullah S AlGhamdi, Abdullah M Assiri, Haziz AlBiladi, Hammad S AlOthmani, Mohammed H Mogharbel, Wedad Mahallawi, Tarik Asselah, Faisal M Sanai   +8 more
doaj   +1 more source

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C

International Journal of Hepatology, Volume 2026, Issue 1, 2026.
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara, Asuka Watanabe, Junya Yamaguchi, Mai Omi, Tetsuro Miyazaki, Haruka Taguchi, Ryosuke Kiyota, Takuo Yamai, Shoichiro Kawai, Takuya Inoue, Takayuki Yakushijin, Dirk Uhlmann   +11 more
wiley   +1 more source

Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. [PDF]

, 2016
Background and aimsAll-oral interferon-free antivirals are highly effective in treating recurrent hepatitis C (HCV) infection in liver transplant (LT) recipients.
Bau, Sherona, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco, El Kabany, Mohammed, Elashoff, David, Farid, Alexander, Grotts, Jonathan, Han, Steven, Jamal, Naadir, Jimenez, Melissa, Rheem, Justin, Saab, Sammy   +12 more
core   +2 more sources

Free‐Form Microfluidic Microneedle Array Patches

Advanced Functional Materials, Volume 35, Issue 52, December 23, 2025.
Microfluidic microneedle array patches (MAPs) integrate hollow microneedles with embedded microfluidic channels, fabricated using high‐resolution 3D printing, to enable controlled transdermal delivery of liquid, mixed, or reconstituted therapeutics.
Ian A. Coates, Madison M. Driskill, Netra U. Rajesh, Gabriel Lipkowitz, Dan Ilyn, Yue Xu, Maria T. Dulay, Gunilla B. Jacobson, John R. Tumbleston, Jillian L. Perry, Shaomin Tian, Joseph M. DeSimone   +11 more
wiley   +1 more source

Changing the face of hepatitis C management – the design and development of sofosbuvir

Drug Design, Development and Therapy, 2015
Bennett C Noell,* Siddesh V Besur,* Andrew S deLemos Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, Charlotte, NC, USA *These authors contributed equally to this work Abstract: The availability of
Noell BC, Besur SV, deLemos AS
doaj